Support the news
On Wednesday, the U.S. Patent and Trademark Office ruled that MIT's Feng Zhang and his team of bio-tech scientists at the Broad Institute of MIT and Harvard can keep their patents for their work on CRISPR gene-editing technology.
For more on this ruling and its implications, patent expert Paul Gugliuzza joined Morning Edition.
This segment aired on February 16, 2017.
- Broad Institute Wins Big Battle Over CRISPR Gene-Editing Patent
- Scientific Panel Says Editing Heritable Human Genes Could Be OK In The Future
- How Gene Editing Could Break The Rules Of Evolution